Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OKI 219

Next Previous
X
Search
Drug Profile

OKI 219

Alternative Names: OKI-219

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OnKure Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 10 Dec 2024 Adverse events and pharmacokinetics data from the phase Ia/Ib PIKture-01 trial in Solid tumours and Breast cancer released by OnKure Therapeutics
  • 05 Apr 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 01 Mar 2024 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, South Korea, Belgium (PO) (NCT06239467)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top